Zoledronic Acid for Bone Metastases From Breast Cancer (6979) A Prospective, Randomized, Double-blind, Stratified, Multi-center, 2-arm Trial of the Continued Efficacy and Safety of Zoledronic Acid (Zometa) (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Breast Cancer.
Phase of Trial: Phase III
Latest Information Update: 21 Jan 2012
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone metastases
- Focus Therapeutic Use
- 27 Apr 2011 New trial record